Navigation Links
Avanir Pharmaceuticals Announces Publication of Phase III Study Results Showing Efficacy and Safety of AVP-923 in the Treatment of Diabetic Neuropathic Pain
Date:2/8/2012

er two applied at five clinic visits.  Safety and tolerability were assessed by adverse event reports, physical examination, electrocardiogram and clinical laboratory tests. Patients with certain cardiac conditions were excluded from the study along with patients taking certain medications.

Study Results

On all six scales, DMQ 45/30 mg was significantly superior to placebo, including the primary efficacy analysis, which utilized mixed-effects modeling to test all scores on an 11-point numerical Pain Rating Scale (p < 0.0001). Sensitivity analyses gave consistent results. Efficacy versus placebo was also seen for diary ratings of present pain intensity, and pain interference with sleep and with activities (all p < 0.0001). Among clinic-visit assessments, DMQ 45/30 mg demonstrated greater leg-pain relief (p = 0.0002) and greater reduction of leg-pain intensity (p = 0.0286) versus placebo. The efficacy of DMQ 30/30 mg was numerically less than for 45/30 mg but for most outcomes remained significantly greater versus placebo. Adverse events were mostly mild or moderate and of expected types. Discontinuation for adverse events in the DMQ groups was at least twice as common as placebo.

About Diabetic Peripheral Neuropathic Pain

Diabetic neuropathic pain, one of the most debilitating forms of pain, is caused by nerve damage that can result from diabetes. It is often described as burning, tingling, stabbing, or pins and needles in the feet, legs, hands or arms. The most frequent form, estimated to affect approximately 50% of diabetic patients, is a distal symmetric polyneuropathy that can involve both small and large sensory fibers. The associated pain, estimated to affect approximately 25% of DPN patients, can be severe and disabling.

About AVP-923

AVP-923 is a combination of two well-characterized compounds: the active ingredient dextromethorphan hydrobromide (an uncompetitive NMDA receptor antagoni
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avanir Pharmaceuticals Reports Fiscal 2011 Fourth Quarter and Year End Financial Results
2. Avanir Pharmaceuticals Announces Date of Fiscal 2011 Fourth Quarter and Year End Financial Results and Conference Call
3. Avanir Pharmaceuticals to Participate in Piper Jaffray Health Care Conference
4. Avanir Pharmaceuticals Announces EMA Acceptance of Marketing Authorization Application for NUEDEXTA
5. Avanir Pharmaceuticals Submits European Marketing Authorization Application for NUEDEXTA
6. Avanir Pharmaceuticals to Present Data at the 2011 American Congress of Rehabilitation Medicine/American Society for Neurorehabilitation Medicine Annual Conference
7. Avanir Pharmaceuticals to Participate in Two Investor Conferences
8. Avanir Pharmaceuticals to Present at Stifel Nicolaus Healthcare Conference
9. Avanir Pharmaceuticals Files Lawsuits Against Par and Actavis for Infringement of NUEDEXTA Patents
10. Avanir Pharmaceuticals Reports Fiscal 2011 Third Quarter Financial Results
11. Avanir Pharmaceuticals Announces Appointment of Dr. Joao Siffert as Senior Vice President Research and Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , February 27, 2015 ... bahnbrechendes Überwachungssystem für kongestive Herzinsuffizienz (CHF) in ...     ... ein neuartiges Herzüberwachungssystem für Patienten mit kongestiver ... dass sie ein Finanzierungsvorhaben über 5 Mio. ...
(Date:2/27/2015)... NEW YORK , Feb. 27, 2015 ... DESI are increasing in applications as their ... research firm Kalorama Information.  Kalorama Information says ... MS) is the most powerful tool in ... (mass spec; MS) through its traditional techniques ...
(Date:2/26/2015)... NORTH CHICAGO, Ill. , Feb. 26, 2015 ... announced that 15 abstracts of studies in its ... for presentation during the 67 th American ... Washington, D.C. , from April 18-25. The ... FDA-approved product, DUOPA, in addition to investigational treatments ...
Breaking Medicine Technology:Vectorious Medical Technologies schließt Finanzierungsvorhaben über 5 Mio. USD ab 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 2Report: "Softer" Mass Spec Techniques Gaining Popularity in Biomarker Discovery 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7
... Oct. 14 Generex Biotechnology Corporation (NasdaqCM: GNBT, ... consideration by stockholders at the reconvened special meeting of ... to approve a proposal to adjourn the special meeting ... previously disclosed in Generex,s proxy statement dated August 23, 2010, ...
... in government policies and regulations may restrict access to ... some homecare equipment providers out of business or to ... and Medicare patients are asking Congress to ensure that ... access for seniors and those living with physical disabilities ...
Cached Medicine Technology:Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010 2Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010 3Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010 4Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010 5Generex Announces That Adjournment Will be Sole Matter Considered at Reconvened Special Meeting of Stockholders on October 15, 2010 6Utah's Seniors and People with Disabilities Will Feel Impact of Medicare Policy Changes that Restrict Access to Power Wheelchairs 2Utah's Seniors and People with Disabilities Will Feel Impact of Medicare Policy Changes that Restrict Access to Power Wheelchairs 3Utah's Seniors and People with Disabilities Will Feel Impact of Medicare Policy Changes that Restrict Access to Power Wheelchairs 4
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims ... platform and gears towards the goal for a better ... group talks in smaller groups will be held after ... Development, Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, Women and ... youths. , Young adults aged between 18-30 ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 In ... Duncan Fletcher of Game Change Athlete ... Shannon Leinert about the benefits of athlete development and ... some of the unique challenges that athletes face and ... and future success. , Fletcher became involved in athlete ...
(Date:2/28/2015)... The Heart Fit Clinic started doing ... the machine. The Heart Fit Clinic is also selling ... franchise model. The goal is to scale the business ... To buy External Counterpulsation machines can be ... through this process and achieve the desired results. ...
(Date:2/28/2015)... February 28, 2015 Mew and Company, ... that they now provide business consulting services in addition ... corporate tax planning and succession planning. Company finances are ... experienced professionals. On top of this, complex Canadian tax ... corporate accounting. As a result, Mew and Company works ...
(Date:2/28/2015)... Carlsbad, CA (PRWEB) February 28, 2015 ... developed a promising new gene therapy procedure for the ... progressive blindness in patients. Authored by Dr. ... Oxford and published in the Lancet Medical Journal on ... suffering from choroideremia, a rare genetic disorder that mostly ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... 4 There are so many health,recommendations in the media ... MOST important changes they can make for better,health in the ... and fitness professionals strong -- for their top,recommendations for the ... in the year ahead. Here are the results of that ...
... Corporation,(NYSE: TMK ) announced today that it ... American Life Insurance Company, and Globe,Life And Accident ... redomesticate other of its subsidiaries to Nebraska this ... number of states, as well as the,Nebraska business ...
... SEGUNDO, Calif., Jan. 4 DaVita Inc. (NYSE:,DVA) ... PLC (,SKI,),have formed a wide-ranging partnership to provide ... kidney disease education and research,in the greater Phoenix ... dialysis centers and programs designed to provide patients ...
... perform implant in February, CHICAGO, Jan. 2 ... to surgically implant the just-approved Nex Gen LPS-Flex,mobile bearing ... Orthopedic,Hospital of Chicago. Last week, the FDA approved the ... of knee prostheses for active,adults, especially amateur and professional ...
... Roxane Laboratories, Inc.,announced today the approval of ... Disodium Capsules, 750mg by the U.S. Food ... bottles of 280 capsules for,immediate shipment to ... http://www.newscom.com/cgi-bin/prnh/20070410/CLTU122LOGO ), Roxane Laboratories, Balsalazide ...
... Ohio, Jan. 3 Bedford Laboratories(TM), a,division ... acquisition of,CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) ... Company. Bedford Laboratories is now the,reference listed ... for,the short term treatment of apnea in ...
Cached Medicine News:Health News:International Sports Sciences Association's Ten Best Resolutions for Better Health in 2008 2Health News:FDA Approves Hi-Flex Mobile Bearing Knee for Active Adults 2Health News:Roxane Laboratories, Inc. Announces the Launch of Balsalazide Disodium Capsules, 750mg 2Health News:Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution 2
... Aegis CheckPoint is an automated, ... logging and alert system for refrigerator, ... replace chart recorders, data loggers and ... installs on an existing PC and ...
... as three tests confirmed Sterillium Rub's extremely ... to FDA (Time Kill study and Tentative ... Products) and one European test - with ... relevant international efficacy specifications. Sterillium Rub with ...
Chlorhexidine Gluconate, exceptionally persistent and broad spectrum antimicrobial properties have led to its recognition as the most effective agent available for surgical scrubbing, hand washing, p...
Amino+Derm moisturizers and soaps are specifically engineered to aid in the prevention of skin irritations and to help maintain healthy, intact skin....
Medicine Products: